Theratechnologies Obtains US Patent for Improving Cognitive Function with Tesamorelin in Patients Suffering from MCI
MarketwiredPress Release: Theratechnologies Inc. – 2 hours 25 minutes ago
MONTREAL, CANADA--(Marketwired - Jul 11, 2013) - Theratechnologies Inc. (TH.TO) today announced that the US Patent and Trademark Office (USPTO) has issued Patent No. 8,481,489 entitled "GH Secretagogues and Uses Thereof" covering a method of improving cognitive function in a subject suffering from mild cognitive impairment (MCI) through the administration of tesamorelin. The patent will expire in 2024.
"We are glad the USPTO delivered this patent as it enlarges the protection of tesamorelin for use in a potential therapeutic area" stated Luc Tanguay, President and Chief Executive Officer of Theratechnologies.
Theratechnologies (TH.TO) is a biopharmaceutical company that specializes in innovative therapeutic peptide products, with an emphasis on growth-hormone releasing factor peptides. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on the SEC's website at www.sec.gov.
NATIONAL Public Relations